NEW YORK (GenomeWeb News) – Shimadzu and Indigo BioSystems announced that they have formed a partnership for the development of clinical mass spectrometry workflows.

Under the partnership, the two firms will combine Shimadzu's mass spec instruments with Indigo's Ascent clinical analysis software, a platform for interpreting mass spec data and automatically reviewing that data for problematic results.

The partnership will focus on developing mass spec solutions for applications in clinical research, forensic toxicology, and drug development, the companies said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.